Trials of the drug show that it can cut recovery time from COVID-19 by nearly a third
TUESDAY, Aug. 11, 2020 (HealthDay News) — Gilead Sciences has applied to the U.S. Food and Drug Administration for approval for its COVID-19 treatment, remdesivir. The antiviral drug will take the brand name Veklury, the company said.
“Today’s filing is an important milestone as we continue to partner with the U.S. government and health care authorities around the globe to address the treatment needs of patients with COVID-19,” Merdad Parsey, M.D., Ph.D., Gilead’s chief medical officer, said in a statement.
At the moment, remdesivir is available on an emergency basis for hospitalized patients with severe COVID-19. If the FDA approves it, however, the drug will gain wider use. Remdesivir is already approved in Europe and Japan. The request for approval comes after the results of a phase 3 trial. The drug works by blocking the virus from copying itself. Trials of the drug showed that it can cut recovery time from COVID-19 by nearly a third.
“Since the beginning of the pandemic, Gilead has worked with urgency to establish the efficacy and safety profile of Veklury, and we now have a robust data set supporting the evaluation of use of the drug across a range of hospitalized COVID-19 patient populations,” Parsey said.
Study IDs Risk Factors for Ketoacidosis in Adults With T2D Receiving SGLT2 Inhibitors 
Anifrolumab Tied to Lower Hospitalization, Infection Risk in Lupus .jpg)
Recommendations Updated for Management of Anemia in CKD 
Therapies Compared for Newly Diagnosed Multiple Sclerosis 
Initial Rx Length Tied to Long-Term Use of Z-Drugs 
Azacitidine + Venetoclax Tied to Improved Event-Free Survival in Adults With AML 
Maintaining Physical Activity Tied to Better Quality of Life With Multiple Sclerosis 
Updated Recommendations Address Medications to Prevent Migraine in Adults 
.jpg)
